General discussion, page-11286

If any shareholder isn't completely aware of the primary endpoint for the OSA trial have a read of this paragraph from a previous company announcement.



This trial has been designed in a fashion were the primary end point will almost definitely be met. From that point it will just be a bonus as to the % of reduction. A 10%+ reduction would be quite significant in my eyes and something that would get a lot of attention.